Trial Profile
Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Figitumumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ADVIGO
- Sponsors Pfizer
- 13 Sep 2022 Results of post-hoc, pooled analysis assessing weight gain and overall survival in patients with non-small cell lung cancer (NSCLC) receiving first-line chemotherapy presented at the 47th European Society for Medical Oncology Congress.
- 07 Jun 2022 Results of post-hoc, pooled analysis from NCT00254891, NCT00254904, and NCT00596830, examining the relationship between weight gain and overall survival (OS) in patients with NSCLC treated with first-line platinum-based regimens, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database.